Angiogenesis inhibitors and vascular-disrupting agents for non-small-cell lung cancer

2014 ◽  
pp. 91-107
Author(s):  
Adam McGeoch
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Angiogenesis Inhibitors ◽  
Small Cell ◽  
Small Cell Lung ◽  
Vascular Disrupting Agents ◽  
Vascular Disrupting

Angiogenesis Inhibitors and Vascular Disrupting Agents in Non-Small Cell Lung Cancer

2009 ◽  
Vol 16 (30) ◽  
pp. 3919-3930 ◽  
Author(s):  
A. Rossi ◽  
P. Maione ◽  
M. Ferrara ◽  
P. Sacco ◽  
C. Schettino ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Angiogenesis Inhibitors ◽  
Small Cell ◽  
Small Cell Lung ◽  
Vascular Disrupting Agents ◽  
Vascular Disrupting

Vascular Disrupting Agents: A Novel Mechanism of Action in the Battle Against Non‐Small Cell Lung Cancer

2009 ◽  
Vol 14 (6) ◽  
pp. 612-620 ◽  
Author(s):  
Cesare Gridelli ◽  
Antonio Rossi ◽  
Paolo Maione ◽  
Emanuela Rossi ◽  
Vincenzo Castaldo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Mechanism Of Action ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Vascular Disrupting Agents ◽  
Vascular Disrupting

scholarly journals Angiogenesis Inhibitors in Small Cell Lung Cancer

2021 ◽  
Vol 11 ◽  
Author(s):  
Agnese Montanino ◽  
Anna Manzo ◽  
Guido Carillio ◽  
Giuliano Palumbo ◽  
Giovanna Esposito ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Predictive Biomarkers ◽  
Angiogenesis Inhibitors ◽  
Small Cell ◽  
Chinese Patients ◽  
Small Cell Lung ◽  
First Line ◽  
Line Setting

Inhibition of angiogenesis has been demonstrated to be an efficacious strategy in treating several tumors. Vascular endothelial growth factor (VEGF) is the most important protein with proangiogenic functions and it is overexpressed in small cell lung cancer (SCLC). Bevacizumab, a monoclonal antibody directed against VEGF, showed a promising activity in combination with etoposide and cisplatin as first-line treatment of patients with extended stage (ES)-SCLC and two randomized studies confirmed that bevacizumab improved PFS, but failed to prolong OS. Instead, disappointing results have been observed with endostar, sunitinib, sorafenib, vandetanib, and thalidomide in combination with chemotherapy in the first-line setting, with sunitinib in the maintenance setting, with sunitinib, cediranib and nintedanib as single agents or ziv-aflibercept in combination with topotecan in second-line setting. Only anlotinib improved OS and PFS as third-line therapy in Chinese patients with SCLC, and it was approved with this indication in China. Future challenges are the evaluation of the role of angiogenesis inhibitors in combination with immune- checkpoint inhibitors and chemotherapy in SCLC patients and the identification of predictive biomarkers of response to both agents.

scholarly journals Angiogenesis inhibitors for the treatment of small cell lung cancer (SCLC)

Medicine ◽  
2017 ◽  
Vol 96 (13) ◽  
pp. e6412 ◽  
Author(s):  
Qing Li ◽  
Tao Wu ◽  
Li Jing ◽  
Miao-Jing Li ◽  
Tao Tian ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Angiogenesis Inhibitors ◽  
Small Cell ◽  
Small Cell Lung

Angiogenesis inhibitors for small cell lung cancer

2017 ◽  
Vol 6 (S3) ◽  
pp. S539-S540
Author(s):  
Sang-Yun Song ◽  
Cheol-Kyu Park ◽  
In-Jae Oh ◽  
Young-Chul Kim
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Angiogenesis Inhibitors ◽  
Small Cell ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document